AbCellera Biologics Inc. priced an oversubscribed underwritten public offering of 17,435,897 common shares at $9.75 per share and pre-funded warrants for up to 3,076,926 additional shares at $9.74999 each. The transaction generates approximately $200 million in gross proceeds and $187 million in net proceeds after underwriting discounts and expenses. Jefferies LLC and J.P. Morgan Securities LLC served as representatives for the underwriters, which also included Cantor Fitzgerald, UBS Investment Bank, and BMO Capital Markets. The offering closed on August 14, 2026, with a 60-day lock-up agreement in place for insiders. AbCellera intends to use the net proceeds to fund research, development, and clinical advancement of its internal pipeline, including lead program ABCL635, as well as for working capital and general corporate purposes. The company operates in the biotechnology industry, focusing on discovering and developing antibody-based medicines.

AbCellera Biologics Inc. announced positive top-line results from the Phase 2 portion of its Phase 1/2 clinical trial for ABCL635, an investigational neurokinin 3 receptor antagonist antibody. The study met primary efficacy endpoints in 92 postmenopausal women, demonstrating a statistically significant reduction in moderate-to-severe vasomotor symptoms after a single subcutaneous dose. At week 4, the treatment group showed an 83% mean percent reduction in symptom frequency compared to 33% for placebo, with a 50 percentage point placebo-adjusted difference. Severity scores decreased by 58% versus 12%, yielding a 46 percentage point adjusted difference. The drug also significantly improved sleep and patient global impression of change, with no serious adverse events reported in the treatment arm. AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines.

On July 29, 2026, AbCellera Biologics Inc. announced a strategic collaboration with Vertex Pharmaceuticals to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. Under the agreement, AbCellera will utilize its proprietary TCE platform to lead discovery and early development activities, while Vertex funds all R&D costs and holds rights to further develop and commercialize resulting therapeutic antibodies. AbCellera is entitled to $28.1 million in total upfront payments and remains eligible for preclinical, development, regulatory, and commercial milestone payments, along with tiered royalties on net sales. The parties may also mutually agree for AbCellera to perform cell line development, process development, and clinical manufacturing through Phase 1. AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing first-in-class antibody-based medicines in areas such as endocrinology, women’s health, immunology, and oncology.

AbCellera Biologics Inc. announced a preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging (TCE) multispecific antibodies. The collaboration will utilize AbCellera's antibody discovery engine to uncover optimized development candidates for gastrointestinal (GI) cancers and other solid tumors. AbCellera Biologics Inc. is a biotechnology company focused on antibody discovery and development.